Search results for "Immunosuppressive treatment"
showing 5 items of 5 documents
Przeszczepy narządowe w okresie epidemii COVID-19
2020
Epidemia COVID-19 zmieniła podejście do kwalifikacji dawców i biorców przeszczepów narządowych. Kwalifikacja następuje po obowiązkowym wykonaniu tomografii komputerowej płuc i testu RT-PCR na obecność wirusa, w wyniku indywidualnej oceny korzyści i ryzyka zakażenia. W bardziej odległym okresie od transplantacji na ciężkość objawów w większym stopniu niż leczenie immunosupresyjne wpływają zaawansowany wiek i współchorobowości. Pierwszym krokiem w redukcji leczenia immunosupresyjnego u biorców przeszczepów narządowych jest odstawienie leku antyproliferacyjnego z pozostawieniem inhibitora kalcyneuryny i steroidów. Terapia immunosupresyjna znamiennie wydłuża czas eliminacji wirusa, ale może ogr…
Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transp…
2019
Abstract Chronic graft-versus-host disease (cGVHD) remains the leading cause of late morbidity and mortality. Despite the growing number of treatment options in cGVHD, evidence remains sparse. The German-Austrian-Swiss GVHD Consortium performed a survey on clinical practice in treatment of cGVHD among transplant centers in Germany, Austria, and Switzerland in 2009 and 2018 and compared the results. The survey performed in 2009 contained 20 questions on first-line treatment and related issues and 4 questions on second-line scenarios followed by a survey on all systemic and topic treatment options known and applied, with 31 of 36 transplant centers (86%) responding. The survey in 2018 repeate…
Resolved versus confirmed ARDS after 24 h: insights from the LUNG SAFE study
2018
Purpose: To evaluate patients with resolved versus confirmed ARDS, identify subgroups with substantial mortality risk, and to determine the utility of day 2 ARDS reclassification. Methods: Our primary objective, in this secondary LUNG SAFE analysis, was to compare outcome in patients with resolved versus confirmed ARDS after 24 h. Secondary objectives included identifying factors associated with ARDS persistence and mortality, and the utility of day 2 ARDS reclassification. Results: Of 2377 patients fulfilling the ARDS definition on the first day of ARDS (day 1) and receiving invasive mechanical ventilation, 503 (24%) no longer fulfilled the ARDS definition the next day, 52% of whom initial…
Noninfectious uveitis: strategies to optimize treatment compliance and adherence.
2015
Noninfectious uveitis includes a heterogenous group of sight-threatening ocular and systemic disorders. Significant progress has been made in the treatment of noninfectious uveitis in recent years, particularly with regard to the effective use of corticosteroids and non-corticosteroid immunosuppressive drugs, including biologic agents. All of these therapeutic approaches are limited, however, by any given patient's ability to comply with and adhere to their prescribed treatment. In fact, compliance and adherence are among the most important patient-related determinants of treatment success. We discuss strategies to optimize compliance and adherence.